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Critical evaluation of plasma and LDL oxidant-trapping poten- Chronic renal failure (CRF) is associated with an in-
tial in hemodialysis patients. creased risk of atherosclerotic cardiovascular disease [1, 2],
Background. We investigated whether the total peroxyl rad- which represents the major cause of mortality in patients
ical-trapping antioxidant potential (TRAP) assay, which has on long-term hemodialysis (HD) [3–5]. Oxidative stress,recently been proposed as a gauge of oxidative stress, could
defined as a rupture in the pro-oxidant–antioxidant bal-serve to evaluate plasma and low density lipoprotein (LDL)
ance in favor of the former, largely participates in theantioxidant state in hemodialysis (HD) patients.
Methods. TRAP was determined by the lag time of the chemi- pathogenesis of atherosclerosis [4, 5]. Interestingly, oxi-
luminescence reaction induced by azo-initiator-catalyzed lino- dative stress has recently been incriminated in the pro-
leic acid peroxidation in the plasma and corresponding LDL gression of renal diseases [6, 7], and culminates in dialysis
preparations of 23 HD patients and 22 healthy subjects. Antiox- patients who combine a massive generation of reactiveidant systems, including glutathione peroxidase (GSH-Px),
oxygen species at each dialysis session [8–12] with a chronicascorbate, vitamin E, and uric acid, oxidative stress markers
deficiency in the major antioxidant systems [13–16]. In-including malondialdehyde (MDA), carbonyls, and advanced
creased serum concentrations of lipid peroxidation by-oxidation protein products (AOPP), and lipids, including cho-
lesterol and triglycerides, were also determined in the plasma. products such as malondialdehyde (MDA) have been
Results. Both plasma and LDL-TRAP were significantly in- reported in HD patients, although with conflicting results
creased in HD patients despite decreased GSH-Px and ascor- [17, 18]. More recently, we reported the presence of
bate and increased MDA, carbonyl, and AOPP plasma levels.
advanced oxidation protein products (AOPPs) as novelPlasma TRAP values were closely related to both uric acid
markers of oxidative stress and proinflammatory media-and AOPP levels, and LDL-TRAP values were related to tri-
tors in both dialyzed [19] and nondialyzed CRF patientsglycerides and AOPP levels. In vitro studies showed that: (a)
plasma TRAP of control plasma increased regularly with sup- [20]. Interestingly, Miyata et al suggested that oxidative
plementation of uric acid, although not reaching that of HD stress could also participate in the formation of advanced
plasma with similar uric acid levels; (b) the addition of human glycation end-products (AGEs) [21, 22] in HD patients,
serum albumin-AOPP also regularly increased control plasma
and we reported the accumulation of the AGE pentosi-TRAP, but was close to that of HD plasma with similar AOPP
dine with the progression of CRF [23].levels; and (c) LDL-TRAP was increased following LDL en-
The total peroxyl radical-trapping antioxidant poten-richment with triglycerides.
Conclusion. Our study demonstrates that TRAP is not a tial (TRAP), measured by the ability of a biological fluid
relevant parameter for evaluating plasma or LDL antioxidant to resist 2,29-azobis [2-amidinopropane] hydrochloride
capacity in HD patients, due to the high plasma levels of uric (ABAP)-induced linoleic acid peroxidation, has recently
acid, triglycerides and AOPP, which by themselves do not exert
been proposed as a useful tool for determining the globalefficient antioxidant activity in vivo, but in vitro are able to
antioxidant capacity of plasma in patients with oxidativescavenge the peroxyl radicals involved in the TRAP assay.
stress-associated diseases such as diabetes [24], sickle
cell disease [25], schizophrenia [26], and cystic fibrosis
[27]. Jackson et al have reported an increased plasmaKey words: total peroxyl radical-trapping antioxidant potential, antiox-
idant, low density lipoprotein, carbonyls, malondialdehyde. TRAP in HD patients and related this finding to the
presence of high circulating levels of uric acid, whichReceived for publication October 9, 1998
because of the profound ascorbate deficiency in theseand in revised form March 15, 1999
Accepted for publication March 22, 1999 patients, has no efficient antioxidant activity in vivo [28].
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(ox-LDL) is a common feature of oxidative stress, and
high levels of ox-LDL have been reported in HD patients
[29, 30]. However, by their triglyceride content and their
capacity to retain liposoluble antioxidants such as vita-
min E, LDLs also contribute to the antioxidant status
[31]. LDL-TRAP has been studied in normal subjects
[32] but has not yet been investigated in HD patients.
This study was aimed at evaluating whether or not the
TRAP assay could be used to quantitate the redox state
of both plasma and LDL of HD patients assessed by
circulating plasma levels of antioxidants including gluta-
thione peroxidase (GSH-Px), ascorbate, vitamin E, and
uric acid and oxidative stress markers, including MDA,
carbonyls, and AOPP.
METHODS
Patients
Twenty-three nonsmoking HD patients (11 males and
12 females; mean age 6 sd, 63 6 15 years) entered
this study after giving informed consent. Patients with
Fig. 1. Time course of luminol-amplified chemiluminescence (CL) ofchronic hepatitis, hematological and inflammatory disor-
2,29-azobis [2-amidinopropane] hydrochloride (ABAP)-catalyzed lino-ders, cancer, and immunosuppressive therapy were ex-
leic acid peroxidation in the presence of normal plasma (a representative
cluded. End-stage renal disease was secondary to inter- experiment). The CL reaction proceeds through the sequence of initia-
tion, propagation, and termination phases and is characterized by itsstitial nephropathy (7 patients), polycystic kidney disease
lag time (t lag), rate, and peak.(4 patients), glomerulonephritis (3 patients), diabetic ne-
phropathy (2 patients), nephroangiosclerosis (1 patient),
or unknown origin (6 patients). All patients were dia-
lyzed for more than three months for 210 to 270 minutes Total peroxyl radical-trapping antioxidant
three times per week with diacetate or triacetate mem- potential assay
brane filters using bicarbonate dialysate. All patients had
Plasma and LDL-TRAP were measured by the delaya serum intact parathyroid hormone level below 250 pg/ml.
in the luminol-amplified chemiluminescence (CL) pro-Twenty-two nonsmoking healthy subjects (9 males and
duction induced by linoleic acid peroxidation initiated13 females, aged 41 6 13 years) were recruited among
by ABAP [32]. Briefly, the generation of peroxyl radicalsthe laboratory staff and served as controls.
was induced by the injection of 100 ml of 250 mm ABAP
(Polysciences Inc., Warrington, PA, USA) in the lumino-Materials
meter (AutoLumat LB 953; Berthold, Wildbad, Ger-If not otherwise indicated, chemicals were purchased
many) cuvette containing the reaction mixture, that is,from Sigma Chemical Co. (St. Louis, MO, USA).
20 ml of 120 mm linoleic acid, 50 ml of 3 mm luminol
(5-amino-2,3-dihydro-1,4-phtalazinedione), and 30 ml ofBlood collection, plasma and low-density
plasma in 470 ml of PBS or 100 ml of LDL in 400 ml oflipoprotein isolation
PBS. The CL reaction proceeds through the sequence
Venous blood (10 ml) from HD patients and controls
of initiation, propagation, and termination phases and
was collected in standard tubes containing 5 mm ethyl-
is characterized by its lag time (t lag), rate, and peak
enediaminetetraacetic acid (EDTA). In HD patients,
(Fig. 1). The CL t lag is lengthened by the presence of
blood was drawn from the arteriovenous fistula just be-
antioxidants such as Troloxt (6-hydroxy-2,5,7,8-tetra-
fore the dialysis session. Following centrifugation (600
methylchroman 2-carboxylic acid; Aldrich, Milwaukee,
g 3 10 min, 48C), plasma was stored at 2808C. LDLs
WI, USA), a water-soluble tocopherol that is used as
from 10 HD patients and 10 control subjects were iso-
a standard for quantitating TRAP measurement [34].
lated by precipitation of 1 ml of plasma with 7 ml of 64
Assuming that each Troloxt molecule neutralizes two
mm citrate buffer, pH 5.05, containing 50,000 IU/liter
peroxyl radicals, TRAP is expressed as follows:
sodium heparinate [33]. After centrifugation, the pellet
was resuspended in 1 ml 100 mm phosphate-buffered TRAP (lmol/liter) 5
[t lagSample/t lagTrolox] 3 Trolox (lmol/liter) 3 2saline (PBS), pH 7.4, containing 0.15 m sodium chloride.
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Lipid and protein oxidative stress markers specifically determining ascorbate, the reduced form of
vitamin C using ascorbate oxidase [37]. Briefly, two ali-Plasma levels of MDA were measured by a highly
quots of 100 ml of plasma were prepared, one with 40sensitive, synchronous fluorescence technique [35].
ml of 4 UI/ml ascorbate oxydase and the other with 40Briefly, 100 ml of plasma were mixed to 750 ml of thiobar-
ml of PBS. The reaction mixture consisted of 10 ml ofbituric acid reagent (Sobioda, Montbonnot, France) in
sample with 30 ml of PBS and 300 ml of reagent preparedacidic condition and boiled for one hour. After extraction
with 10 ml of 300 mm acetate buffer, pH 3.6, 1 ml of 10with 3 ml of N-butanol, the spectrum of the organic layer
mm 2,4,6-tripyridyl-s-triazine (TPTZ) in 0.04 n HCl, andwas recorded on a spectrophotometer (Shimadzu RF540,
1 ml of 20 mm ferric chloride. The reduction of Fe31-Roucaire, Courtaboeuf, France) between 500 and 600
TPTZ in the Fe21-TPTZ blue form was measured atnm keeping a constant interval, that is, Dl of 14 nm
593 nm after an incubation of 45 seconds at 378C. Thebetween excitation and emission wavelengths. The MDA
ascorbate plasma level was calculated by the differenceconcentration was calculated by the fluorescence peak
between absorption of sample with and without ascor-intensity at 553 nm using tetramethoxypropane, which
bate oxidase. Ascorbate (0 to 250 mm) (Merck, Darm-produces MDA, as the standard.
stadt, Germany) was used as the standard.Plasma levels of carbonyls were measured by a spec-
Plasma levels of vitamin E were determined by a re-trophotometric procedure using 2,4-dinitrophenylhy-
verse high-performance liquid chromatography (HPLC)drazine (DNPH) [36]. Briefly, plasma was treated with
procedure as described in [38], after deproteinization of10 mm DNPH in 2.5 mm HCl. After incubation for one
200 ml of plasma with 200 ml of anhydrous HPLC-gradehour at room temperature in the dark, deproteinization
ethanol. Briefly, after vitamin E extraction with 400 ml ofwith 20% (wt/vol) trichloracetic acid was realized at 48C.
HPLC-grade heptane, the organic layer was evaporatedThe pellet was washed three times in ethanol/ethyl ace-
under a nitrogen stream and the dry extract was redis-tate (1:1, vol/vol) and then solubilized at 378C for 30
solved in 400 ml of HPLC-grade methanol. One hundredminutes in 6 m guanidine hydrochloride, pH 2.3. Carbonyls
microliters of the sample were injected in a 250 3 4.6 mm,were measured using molar absorption coefficient e of
5 mm ODS-C18 column (Satisfaction RP18AB; Cluzeau,22,000 m21cm21 at 370 nm and expressed in nmol/mg of
Ste Foy La Grande, France), and eluted with HPLC-protein measured at 280 nm by referring to bovine serum
grade methanol at a flow rate of 2 ml/min. Detection wasalbumin.
by ultraviolet absorbance at 292 nm. Internal and externalPlasma levels of AOPP were measured as previously
standards consisted in a-tocopherol and a-tocopheroldescribed in our laboratory [19] by a spectrophotometric
acetate, respectively.assay using a microplate reader MR5000 (Dynatech,
Plasma levels of uric acid were determined using aParis, France) at 340 nm. Briefly, 200 ml of a fivefold
Hitachi 917 analyzer (Boehringer Mannheim, Meylan,dilution of plasma in 10 mm PBS were placed in a 96-well
France) with commercially available kits.plate (Nunc-immuno plate; Nunc, Roskilde, Denmark)
and mixed with 20 ml acetic acid. AOPP concentrations
Lipid determinationswere expressed in mmol/liter by referring to standard
Cholesterol and triglycerides were determined in thewells, containing 200 ml of chloramine-T solution (0 to
plasma and/or LDL preparations (for triglycerides) using100 mm), 10 ml of 1.16 m potassium iodide, and 20 ml of
a Hitachi 917 analyzer.acetic acid.
Advanced oxidation protein productsAntioxidant systems in plasma
in vitro preparationSeleno-dependent GSH-Px activity was measured in
Human serum albumin (HSA; fraction V; CalBio-plasma using tert-butyl hydroperoxide as described previ-
chem, Mendon, France) was oxidized with hypochlorousously [6]. Briefly, the reaction mixture consisting of 1 mm
acid (HOCl) as described by Witko-Sarsat et al [19].reduced glutathione, 1 mm tert-butyl hydroperoxide, 230
Briefly, HSA (100 mg/ml) was incubated at room temper-IU/liter of yeast glutathione reductase, 0.143 mm nicotin-
ature for 15 minutes with 100 mm HOCl (HOCl:proteinamide adenine dinucleotide phosphate (NADPH), and
molar ratio of 60:1) and then dialyzed overnight against1.5 mm potassium cyanide in 100 mm PBS. The assay
10 mm PBS, pH 7.4.kinetics were calculated using molar absorption coeffi-
cient e for NADPH of 6.22 3 1023 m21 cm21. GSH-Px
Statistical analysisactivity was expressed in millimoles of NADPH oxidized
Data were expressed as means 6 sd. Statistical analy-per milliliter (IU/liter).
sis was performed using the Mann–Whitney U-test forPlasma levels of vitamin C were measured by an auto-
nonparametric data. Simple regression analysis and Spear-mated enzyme-linked ferric-tripyridyltriazine spectro-
photometric assay (Cobas Fara, Roche, Meylan, France) man’s rank correlation coefficients were calculated to
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Table 2. Plasma levels of antioxidant systems, oxidative stressTable 1. Chemiluminescence (CL) reaction parameters and total
peroxyl radical-trapping antioxidant potential (TRAP) values of markers and lipids in hemodialysis (HD) patients as compared
to healthy control subjectsplasma and low density lipoprotein (LDL) preparation from
hemodialysis (HD) patients as compared to healthy control subjects
HD patients Control subjects
(N523) (N522)HD patients Control subjects
Number 23 22 Antioxidant systems
GSH-Px IU/liter 2369b 72614CL lag time min 39.367.8c 23.264.7
CL rate /10 7 cpm 2.961.3c 7.362.5 Ascorbate lmol /liter 16615b 61619
Vitamin E lmol /liter 28.066.4 28.5 67.2CL peak /10 7 cpm 6.162.3c 14.564.0
Plasma TRAP lmol /liter 13286255b 7836159 Uric acid lmol /liter 396685b 262661
Lipid and protein oxidation products
Number 10 10 MDA lmol /liter 3.260.7b 2.460.2
CL lag time min 7.862.7a 4.361.5 Carbonyls nmol/mg protein 0.7360.32a 0.3160.09
CL rate /10 7 cpm 5.862.4 6.962.4 AOPP lmol /liter 147647b 38617
CL peak /10 7 cpm 9.261.8 9.061.1 Lipids
LDL-TRAP mmol /liter 108638a 60621 Cholesterol mmol /liter 5.361.2 5.3 60.9
Triglycerides mmol /liter 2.060.9b 1.060.5Values are expressed as mean 6 sd. P values, as determined by Mann-Whitney
U test are: a P , 0.05, b P , 0.001, c P , 0.0001
Values are expressed as mean 6 sd. P values were determined by the Mann-
Whitney U test. Abbreviations are: AOPP, advanced oxidation protein products;
MDA, malondialdehyde; GSH-Px, glutathione peroxidase.
a P , 0.001, a P , 0.0001
assess the relationship between the various parameters.
The threshold of statistical significance was P , 0.05.
were not correlated with these antioxidants but were
RESULTS positively correlated with plasma levels of vitamin E (r 5
0.62, P , 0.01).Plasma and LDL-TRAP in hemodialysis patients and
In contrast to other antioxidants, uric acid was signifi-control subjects
cantly higher in the plasma of HD patients than of controlPlasma from HD patients significantly increased lag
subjects, and its level was positively correlated withtime and reduced both the rate and peak of the CL
plasma TRAP (r 5 0.70, P , 0.0001) but not with LDL-reaction as compared with control plasma (Table 1). LDL
TRAP values.preparations from HD patients also significantly increased
CL lag time but had no effect on the CL rate or peak. Relationship between TRAP and plasma levels of
Therefore TRAP, which only accounts for CL lag time, lipid and protein oxidation products
was significantly higher in HD patients than in controls
Malondialdehyde, carbonyl, and AOPP concentra-and for both plasma (P , 0.001) and LDL (P , 0.05;
tions were significantly increased in the plasma of HDTable 1). Moreover, a positive correlation was observed
patients as compared with controls (Table 2).between plasma TRAP and LDL-TRAP values (r 5
Plasma TRAP values were positively correlated with0.54, P , 0.05).
plasma levels of carbonyls (r 5 0.42, P , 0.02) andBecause previous studies have reported profound
AOPP (r 5 0.59, P , 0.0001) but not MDA. In contrast,changes in antioxidant systems with aging [39, 40], we
LDL-TRAP values were correlated with both MDA (r 5compared plasma TRAP values in HD patients aged less
0.60, P , 0.01) and AOPP (r 5 0.60, P , 0.01) but notthan 50 years (N 5 7) or $50 years (N 5 16) to those
with carbonyl plasma levels.in healthy controls aged less than 50 years (N 5 18).
Plasma TRAP values (mean 6 sd) were similar in HD
Relationship between TRAP and plasma lipid levelspatients ,50 years or $50 years (1364 6 227 and 1290 6
Whereas plasma cholesterol levels were similar in HD264 mmol/liter, respectively) and were significantly higher
patients and control subjects, plasma triglyceride levelsin HD patients ,50 years than in controls ,50 years
were significantly higher in the former (Table 2).(1364 6 227 vs. 775 6 161 mmol/liter, P , 0.01).
Although no correlation was found between plasma
Relationship between TRAP and plasma levels of TRAP and triglyceride levels, a positive correlation was
antioxidant systems observed between LDL-TRAP values and plasma tri-
glyceride levels (r 5 0.64, P , 0.01).Plasma levels of GSH-Px and ascorbate were signifi-
cantly decreased in HD patients as compared with con-
In vitro effect of compounds correlating with thetrols (Table 2). In contrast, plasma levels of vitamin E
TRAP in vivowere similar in HD patients and in control subjects.
The positive correlations observed between, on thePlasma TRAP values were inversely correlated with
one hand, plasma TRAP and uric acid or AOPP plasmaGSH-Px (r 5 20.59, P , 0.01) and ascorbate (r 5 20.54,
P , 0.01) plasma levels. In contrast, LDL-TRAP values levels and, on the other hand, LDL-TRAP and triglycer-
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HD [5, 6, 14–16]. Recently, TRAP has been proposed as
a relevant parameter to determine the total antioxidant
capacity of plasma from patients with oxidative stress-
associated diseases [24–27]. In contrast, the antioxidant
potential of LDL has not yet been investigated, although
it could be of great interest in the evaluation of the role
of ox-LDL in the atherosclerosis process.
This study aimed at determining the potential clinical
relevance of the TRAP parameter to gauge the redox
state of HD patients showed that in fact both plasma
and LDL-TRAP were significantly increased in these
patients as compared with controls (Table 1). This was
found despite high circulating levels of oxidative stress
markers, including MDA, carbonyls, and AOPP, and
a profound deficiency of major antioxidants, including
GSH-Px and ascorbate but not vitamin E (Table 2), the
activity of which, however, is known to be consistentlyFig. 2. Effect of in vitro supplementation, respectively, 100 mM (a)
impaired when the ascorbate level is reduced [41]. Theand 200 mM (b) uric acid and 100 mM (c) and 200 mM (d ) HSA-AOPP
preparation to a normal plasma (heavy line) on the CL reaction as inverse relationship found between plasma TRAP and
compared with a hemodialysis patient plasma (dashed line; results of plasma levels of GSH-Px or ascorbate further demon-a typical experiment).
strated that the capacity to scavenge peroxyl radicals in
vitro did not reflect the activity of the major plasma
antioxidant systems. Rather, it suggested the presence
of other substances in the plasma of uremic patients thatides or AOPP led us to perform an in vitro study of the
are not necessarily efficient chain-breaking antioxidantseffect of these plasma compounds on the TRAP assay.
in vivo, but are able to exert a peroxyl radical-scavengingThe addition of uric acid to control plasma did not
effect in vitro. Among these, uric acid is a good candidate.influence the CL rate and peak, but significantly in-
Uric acid is usually an efficient antioxidant in vitro. How-creased the CL lag time in a dose-dependent manner
ever, this is less the case in vivo in the presence of de-(Fig. 2). Thus, normal plasma TRAP regularly increased
creased ascorbate levels [42]. In addition, it has beenwith uric acid supplementation, although it did not reach
shown that uric acid is not efficient against oxidant-medi-that of HD patients having similar circulating uric acid
ated protein damage [43].levels (Table 3).
Interestingly, Jackson et al also found that plasmaThe addition of HSA-AOPP preparations to normal
TRAP was higher in HD patients than in controls andplasma significantly increased the CL time lag and de-
that it was significantly decreased by the end of a singlecreased both the CL rate and peak (Fig. 2). The CL
dialysis session [28]. They attributed these observationsreaction pattern of control plasma supplemented with
to uric acid, which is present at high plasma levels before150 mm HSA-AOPP was close to that given by HD plasma
the dialysis session and dramatically decreases at the endcontaining a mean AOPP level of 174 6 14 mmol/liter
of the session. Our in vitro study showed that the addition(Table 3).
of uric acid to normal plasma increased its TRAP in aFinally, we investigated the effect of triglycerides on
dose-dependent manner and thus further supported theLDL-TRAP by adding to a normal plasma LDL prepa-
major influence of uric acid on TRAP assay. However,ration (containing 0.43 mmol/liter triglycerides), a tri-
our observation that the control plasma TRAP obtainedglyceride-rich LDL preparation (containing 0.71 mmol/
after uric acid supplementation was still lower than thatliter triglycerides), or triolein (3 mmol/liter), a triglycer-
of an HD plasma with a similar uric acid level (Table 3)ide that is not integrated in LDL particles. Although
strongly suggested that other uremia-related substancestriolein had no effect on LDL-TRAP, a moderate in-
contributed to the increase in plasma TRAP of HD pa-crease in the CL time lag (from 2.8 6 0.5 to 4.5 6 0.8 min)
tients.was observed following the addition of the triglyceride-
Among these, AOPP, which we have recently pro-enriched LDL preparation.
posed as novel uremic toxins and molecular basis of oxida-
tive stress [44, 45], should be considered despite the fact
DISCUSSION that they do not exert proper antioxidant activity. In-
Several groups, including ours, have highlighted the deed, Hawkins and Davies have previously reported that
role of antioxidant depletion in the progression of CRF oxidized proteins become more avid than native proteins
for trapping radicals [43]. It is thus tempting to proposeand the complications associated with its treatment by
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Table 3. Effect of uric acid and HSA-AOPP on plasma CL reaction and TRAP
Control plasma Control plasma supplemented with uric acid or AOPP HD plasma
Uric acid lmol /liter 245615 1100 1200 No No 432618
AOPP lmol /liter 31610 No No 1100 1150 174614
CL reaction
lag time min 19.762.0 23.061.6a 31.562.0b 23.861.1a 29.562.8b 37.661.0b
rate /10 7 cpm 5.961.3 5.761.0 5.860.9 3.360.8b 2.860.6b 2.761.0b
peak /10 7 cpm 11.961.4 11.560.5 10.961.0 6.260.8b 5.160.5b 5.560.4b
TRAP lmol /liter 624629 691626a 1005637b 745630a 1019645b 1223659c
Results of 5 experiments are shown (mean 6 sd). P values were by the Mann-Whitney U-test versus control plasma before supplementation.
a P , 0.05, b P , 0.01, c P , 0.001
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APPENDIXlevels but not with MDA levels, and (b) in vitro supple-
Abbreviations used in this article are: ABAP, 2,29-azobis [2-amidi-mentation of normal plasma with HSA-AOPP prepara-
nopropane] hydrochloride; AGEs, advanced glycation end-products;tions significantly increased TRAP values (Table 3) sup- AOPPs, advanced oxidation protein products; CL, chemiluminescence;
port this hypothesis. CRF, chronic renal failure; DNPH, 2,4-dinitrophenylhydrazine; GSH-
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ments. The presence of ox-LDL, as a consequence of phosphate; ox-LDL, oxidized low-density lipoprotein; t lag, lag time;
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